Literature DB >> 23962908

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Daniel J Klein1, Caroline F Thorn, Zeruesenay Desta, David A Flockhart, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23962908      PMCID： PMC4084801          DOI： 10.1097/FPC.0b013e3283656bc1

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  51 in total

1.  SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.

Authors:  Ann M Moyer; Vera J Suman; Richard M Weinshilboum; Rajeswari Avula; John L Black; Stephanie L Safgren; Mary J Kuffel; Matthew M Ames; James N Ingle; Matthew P Goetz
Journal:  Pharmacogenomics       Date:  2011-10-03       Impact factor: 2.533

2.  Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments?

Authors:  Chris H Takimoto
Journal:  Nat Clin Pract Oncol       Date:  2007-01-23

3.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.

Authors:  Silvana Borges; Zeruesenay Desta; Lang Li; Todd C Skaar; Bryan A Ward; Anne Nguyen; Yan Jin; Anna Maria Storniolo; D Michele Nikoloff; Lin Wu; Grant Hillman; Daniel F Hayes; Vered Stearns; David A Flockhart
Journal:  Clin Pharmacol Ther       Date:  2006-07       Impact factor: 6.875

4.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Authors:  Susan Nowell; Carol Sweeney; Maria Winters; Angie Stone; Nicholas P Lang; Laura F Hutchins; Fred F Kadlubar; Christine B Ambrosone
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

5.  Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases.

Authors:  Josie L Falany; Daniel E Pilloff; Thomas S Leyh; Charles N Falany
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

6.  Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.

Authors:  Priyanka Parte; David Kupfer
Journal:  Drug Metab Dispos       Date:  2005-06-29       Impact factor: 3.922

7.  Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.

Authors:  Wenjie Jessie Lu; Zeruesenay Desta; David A Flockhart
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

8.  Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.

Authors:  Dongxiao Sun; Arun K Sharma; Ryan W Dellinger; Andrea S Blevins-Primeau; Renee M Balliet; Gang Chen; Telih Boyiri; Shantu Amin; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2007-07-30       Impact factor: 3.922

9.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Authors:  James M Rae; Suzy Drury; Daniel F Hayes; Vered Stearns; Jacklyn N Thibert; Ben P Haynes; Janine Salter; Ivana Sestak; Jack Cuzick; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

10.  Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.

Authors:  Pia Wegman; Linda Vainikka; Olle Stål; Bo Nordenskjöld; Lambert Skoog; Lars-Erik Rutqvist; Sten Wingren
Journal:  Breast Cancer Res       Date:  2005-01-28       Impact factor: 6.466
View more
  34 in total

1.  In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Authors:  Daniel L Hertz; Anna C Snavely; Howard L McLeod; Christine M Walko; Joseph G Ibrahim; Steven Anderson; Karen E Weck; Gustav Magrinat; Oludamilola Olajide; Susan Moore; Rachel Raab; Daniel R Carrizosa; Steven Corso; Garry Schwartz; Jeffrey M Peppercorn; James P Evans; David R Jones; Zeruesenay Desta; David A Flockhart; Lisa A Carey; William J Irvin
Journal:  Br J Clin Pharmacol       Date:  2015-08-02       Impact factor: 4.335

2.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

3.  Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.

Authors:  Nehad M Ayoub; Amer E Alkhalifa; Dalia R Ibrahim; Ahmed Alhusban
Journal:  Med Oncol       Date:  2021-01-15       Impact factor: 3.064

Review 4.  Progress towards the integration of pharmacogenomics in practice.

Authors:  Sean D Mooney
Journal:  Hum Genet       Date:  2014-09-11       Impact factor: 4.132

Review 5.  Neurodegenerative Disease: Roles for Sex, Hormones, and Oxidative Stress.

Authors:  Nathalie Sumien; J Thomas Cunningham; Delaney L Davis; Rachel Engelland; Oluwadarasimi Fadeyibi; George E Farmer; Steve Mabry; Paapa Mensah-Kane; Oanh T P Trinh; Philip H Vann; E Nicole Wilson; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

6.  Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.

Authors:  Cathrine F Hjorth; Anja S Nielsen; Henrik T Sørensen; Timothy L Lash; Per Damkier; Stephen Hamilton-Dutoit; Deirdre Cronin-Fenton
Journal:  Acta Oncol       Date:  2018-11-20       Impact factor: 4.089

7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Authors:  Matthew P Goetz; Katrin Sangkuhl; Henk-Jan Guchelaar; Matthias Schwab; Michael Province; Michelle Whirl-Carrillo; W Fraser Symmans; Howard L McLeod; Mark J Ratain; Hitoshi Zembutsu; Andrea Gaedigk; Ron H van Schaik; James N Ingle; Kelly E Caudle; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2018-01-31       Impact factor: 6.875

8.  Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.

Authors:  Calley J Jones; Malayannan Subramaniam; Michael J Emch; Elizabeth S Bruinsma; James N Ingle; Matthew P Goetz; John R Hawse
Journal:  Mol Cancer Res       Date:  2021-02-24       Impact factor: 5.852

9.  No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats.

Authors:  Kanumuri Siva Rama Raju; Isha Taneja; Guru Raghavendra Valicherla; Murali Krishna Challagundla; Mamunur Rashid; Anees Ahmed Syed; Jiaur Rahman Gayen; Sheelendra Pratap Singh; Muhammad Wahajuddin
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

10.  Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.

Authors:  Benjamin Wolfson; Michelle R Padget; Jeffrey Schlom; James W Hodge
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.